ClinicalTrials.gg
TerminatedNCT04579666Updated Apr 24, 2025Results posted

MERIDIAN: A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2 interventional study of Pegcetacoplan (APL-2) and Placebo in Amyotrophic Lateral Sclerosis and Motor Neuron Disease, sponsored by Apellis Pharmaceuticals, Inc.. Terminated at 60 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-24.

Sponsored by Apellis Pharmaceuticals, Inc. (part of Biogen) · Phase 2, Interventional, and Treatment

Why this study was terminated
The study did not meet primary endpoint at Week 52. The study also did not meet key secondary efficacy endpoints. Pegcetacoplan (APL-2) was well tolerated in the study, and the data were consistent with the established safety profile.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
249
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Amyotrophic Lateral Sclerosis by Biogen — 2 open to participants now, 4 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · Biogen.

Started
2020
with 2 others
Phase 2
Only one
of the 11
Registered
7th of 11
by date

Among the 11 studies in Amyotrophic Lateral Sclerosis by Biogen, this one is one of 3 that started in 2020, is the only one in phase 2, and was the 7th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

2 of the 11 studies in Amyotrophic Lateral Sclerosis by Biogen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Amyotrophic Lateral Sclerosis by Biogen, or all of them as a file.
02

Study summary

This is a 24-month, Phase 2, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of pegcetacoplan in subjects with amyotrophic lateral sclerosis (ALS)

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • Motor Neuron Disease

Keywords

  • Amyotrophic Lateral Sclerosis
  • ALS
  • Motor Neuron Disease
  • APL-2
  • APL2
  • Pegcetacoplan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Sporadic ALS diagnosed as definite, probable, or laboratory-supported probable as defined by the revised El Escorial criteria
  • Slow vital capacity (SVC) ≥60% of the predicted value at screening
  • Onset of ALS symptoms within 72 weeks (18 months) prior to screening
  • Total ALSFRS-R score of ≥30 at screening
  • Have vaccination within 5 years against Streptococcus pneumoniae, Neisseria meningitidis (types A, C, W, Y, and B), and Haemophilus influenzae (type B) or agree to receive vaccination

Exclusion criteria

Exclusion Criteria:

  • Confirmed or suspected other causes of neuromuscular weakness
  • Diagnosed with another neurodegenerative disease (examples include Parkinson's disease and Huntington's disease)
  • Significant pulmonary disorder not attributed to ALS (eg, , pulmonary fibrosis, cystic fibrosis, pulmonary arterial hypertension)
  • If taking riluzole, participant must be on a stable dose for 30 days prior to the start of the screening period. Use of riluzole is not required for participation.
  • If taking edaravone, participant must be on a stable dose for 60 days prior to the start of the screening period. Use of edaravone is not required for participation.
  • Participation in any other drug trial or exposure to other investigational agent, device, or procedure within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation
  • Use of any other complement inhibitor within 30 days or within 5-half lives of the treatment (whichever is longer) prior to the start of the screening period or during study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
249 participants (actual)

Study arms

  • Experimental
    1,080 mg pegcetacoplan (APL-2)

    administered subcutaneously twice weekly

    Drug: Pegcetacoplan (APL-2)

  • Placebo comparator
    Placebo administered subcutaneously twice weekly

    Other: Placebo

Interventions

  • Complement (C3) Inhibitor

  • OtherPlacebo

    Sterile solution of equal volume to active arm

06

What researchers measure

Primary outcomes

  1. RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52

    The CAFS scale is a combined endpoint ranking subjects' clinical outcomes based on ALS Functional Rating Scale-Revised (ALSFRS-R-described below) and survival time. For ALSFRS-R, 12 functions were rated on 5-point ordinal rating scales (0 to 4) with a total score range of 0-48 (sum of all 12 items); higher score indicated better functioning. For survival time, longer the subject survives indicated better outcome. Each subject's outcome was compared to every other subject outcome in trial in series of pairwise comparisons, summed scores (sum of comparisons \[+1 {better}, 0 {tie}, -1 {worse}\]) were ranked and ranged from 001-247 (number of subjects in modified \[m\]ITT population).Reported values are the least squares mean rank scores in each group for the composite endpoint. Higher rank indicated better outcome.

    Time frame: Week 52

  2. RTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.

    Time frame: From first dose of study drug (Day 1) up to 56 days post last dose of study drug, approximately 60 weeks

  3. OLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events

    An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.

    Time frame: From first dose of study drug (Week 52) up to 56 days post last dose of study drug, approximately 60 weeks

  4. RTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52

    The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of suicidal ideation (SI) and suicidal behavior (SB).C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale: 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) up to Week 52

  5. OLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104

    The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of SI and SB.C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale:1 (preparatory acts or behavior),2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration in OLP.

    Time frame: From Baseline (Week 52) up to Week 104

Secondary outcomes

  1. RTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52

    The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Least squares mean is presented here. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) and Week 52

  2. RTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52

    SVC is a pulmonary function test and predictor of functional loss in ALS. It was conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) and Week 52

  3. RTP: Change From Baseline in Muscle Strength at Week 52

    Muscle strength was measured using handheld dynamometry (HHD) and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Day 1) and Week 52

  4. RTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 52

    Subjects with an event (that is, either death or permanent tracheostomy or permanent assisted ventilation) in RTP are reported.

    Time frame: Baseline (Day 1) up to Week 52

  5. RTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 52

    The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related quality of life (QoL) over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was calculated by adding the 5 dimension scores; least squares mean is presented here. Higher scores indicated worse QoL.

    Time frame: Baseline (Day 1) and Week 52

  6. OLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104

    The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Mean is presented here. Baseline was defined as the last observed value for the efficacy assessment prior to taking the first dose of study drug in OLP.

    Time frame: Baseline (Week 52) and Week 104

  7. OLP: Change From Baseline in Percent Predicted Slow Vital Capacity at Week 104

    SVC is a pulmonary function test and predictor of functional loss in ALS. It was planned to be conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Week 52) and Week 104

  8. OLP: Change From Baseline in Muscle Strength at Week 104

    Muscle strength was planned to be measured using HHD and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

    Time frame: Baseline (Week 52) and Week 104

  9. OLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104

    Subjects with an event of death are reported. Subjects were planned to be assessed for permanent tracheostomy or permanent assisted ventilation in OLP; however, that data was not collected as study was terminated early.

    Time frame: Baseline (Week 52) and Week 104

  10. OLP: Change From Baseline in ALS Assessment Questionnaire-40 at Week 104

    The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related QoL over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was planned to be calculated by adding the 5 dimension scores. Higher scores would have indicated worse QoL.

    Time frame: Baseline (Week 52) and Week 104

  11. Number of Subjects With an Event of Death During the Study

    Total number of subjects who died in the study are reported.

    Time frame: RTP: Baseline (Day 1) up to Week 52; OLP: Baseline (Week 52) up to Week 104

07

Results

Posted Apr 24, 2025
Limitations and caveats
The study was terminated early, during the OLP, due to lack of efficacy as determined by the Week 52 data and no safety concerns.

Participant flow

This Phase 2, placebo-controlled study was conducted in subjects diagnosed with amyotrophic lateral sclerosis (ALS). A total of 249 subjects were randomized in a 2:1 ratio to either receive pegcetacoplan or placebo.

RTP (Up to Week 52)
Participant flow — RTP (Up to Week 52)
MilestoneRTP: PegcetacoplanRTP: PlaceboOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
Started1698000
Completed995100
Not completed702900
Withdrew: Adverse event4300
Withdrew: Death24900
Withdrew: Lost to follow-up1000
Withdrew: Physician decision4100
Withdrew: Progressive disease1000
Withdrew: Site terminated by sponsor7500
Withdrew: Study terminated by sponsor2000
Withdrew: Withdrawal by subject251100
Withdrew: Other2000
OLP (From Week 52 up to Week 104)
Participant flow — OLP (From Week 52 up to Week 104)
MilestoneRTP: PegcetacoplanRTP: PlaceboOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
Started009750
Completed0000
Not completed009750
Withdrew: Adverse event0020
Withdrew: Withdrawal by subject001912
Withdrew: Sponsor request006331
Withdrew: Physician decision0031
Withdrew: Death00106

Outcome measures

PrimaryRTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52

The CAFS scale is a combined endpoint ranking subjects' clinical outcomes based on ALS Functional Rating Scale-Revised (ALSFRS-R-described below) and survival time. For ALSFRS-R, 12 functions were rated on 5-point ordinal rating scales (0 to 4) with a total score range of 0-48 (sum of all 12 items); higher score indicated better functioning. For survival time, longer the subject survives indicated better outcome. Each subject's outcome was compared to every other subject outcome in trial in series of pairwise comparisons, summed scores (sum of comparisons \[+1 {better}, 0 {tie}, -1 {worse}\]) were ranked and ranged from 001-247 (number of subjects in modified \[m\]ITT population).Reported values are the least squares mean rank scores in each group for the composite endpoint. Higher rank indicated better outcome.

Time frame:
Week 52
Reported as:
Least squares mean · score on a scale
RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52
score on a scaleRTP: PegcetacoplanRTP: Placebo
RTP: Combined Assessment of Function and Survival (CAFS) Rank Score (Joint-Rank Score) at Week 52123.0 ± 4.71126.0 ± 6.89
Statistical analysis
  • RTP: Pegcetacoplan vs RTP: Placebo · ANCOVA · p = 0.7205 · Difference in ls mean: -3.0 · 95% CI -19.5 to 13.5
PrimaryRTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.

Time frame:
From first dose of study drug (Day 1) up to 56 days post last dose of study drug, approximately 60 weeks
Reported as:
Count of participants · Participants
RTP: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
ParticipantsRTP: PegcetacoplanRTP: Placebo
TEAEs13761
TESAEs5727
PrimaryOLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events

An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not it was considered drug related. An SAE was any AE or suspected adverse reaction that, in the view of the investigator, resulted in death, was life threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or was a congenital anomaly or birth defect. TEAEs were AEs that started on or after first dose of study drug or started before first dose of study drug but increased in severity on or after the first dose of study drug up to 56 days post last dose of study drug.

Time frame:
From first dose of study drug (Week 52) up to 56 days post last dose of study drug, approximately 60 weeks
Reported as:
Count of participants · Participants
OLP: Number of Participants With Treatment-emergent Adverse Events and Treatment-emergent Serious Adverse Events
ParticipantsOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
TEAEs5433
TESAEs2414
PrimaryRTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52

The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of suicidal ideation (SI) and suicidal behavior (SB).C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale: 1 (preparatory acts or behavior), 2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) up to Week 52
Reported as:
Count of participants · Participants
RTP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale (C-SSRS) up to Week 52
ParticipantsRTP: PegcetacoplanRTP: Placebo
SI only166
SB only00
SI and SB10
PrimaryOLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104

The C-SSRS is a measure used to identify and assess individuals at risk for suicide and included "yes" or "no" responses for assessment of SI and SB.C-SSRS SI items are classified on 5-item scale:1 (wish to be dead),2 (non-specific active suicidal thoughts),3 (active SI with any methods without intent to act),4 (active SI with some intent to act, without specific plan) and 5 (active SI with a specific plan and intent).C-SSRS SB items are classified on 5-item scale:1 (preparatory acts or behavior),2 (aborted attempt), 3 (interrupted attempt), 4 (actual attempt \[non-fatal\]) and 5 (completed suicide). Numeric ratings were provided for SI (1 to 5) and SB (1 to 5) with 5 being more severe for each. Number of subjects with a response of 'yes' to SI only, SB only \& SI and SB are reported. Baseline: last available, non-missing observation prior to first study drug administration in OLP.

Time frame:
From Baseline (Week 52) up to Week 104
Reported as:
Count of participants · Participants
OLP: Number of Subjects With Positive Response to Columbia-Suicide Severity Rating Scale up to Week 104
ParticipantsOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
SI only113
SB only00
SI and SB10
SecondaryRTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52

The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Least squares mean is presented here. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · score on a scale
RTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52
score on a scaleRTP: PegcetacoplanRTP: Placebo
RTP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Score at Week 52-16.5 ± 0.81-15.8 ± 1.20
Statistical analysis
  • RTP: Pegcetacoplan vs RTP: Placebo · MMRM · p = 0.6447 · Difference in ls mean: -0.7 · 95% CI -3.5 to 2.2
SecondaryRTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52

SVC is a pulmonary function test and predictor of functional loss in ALS. It was conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · percentage of predicted SVC
RTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52
percentage of predicted SVCRTP: PegcetacoplanRTP: Placebo
RTP: Change From Baseline in Percent Predicted Slow Vital Capacity (%SVC) at Week 52-39.2 ± 2.30-32.6 ± 3.17
Statistical analysis
  • RTP: Pegcetacoplan vs RTP: Placebo · MMRM · p = 0.0949 · Difference in ls mean: -6.6 · 95% CI -14.3 to 1.2
SecondaryRTP: Change From Baseline in Muscle Strength at Week 52

Muscle strength was measured using handheld dynamometry (HHD) and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · pounds
RTP: Change From Baseline in Muscle Strength at Week 52
poundsRTP: PegcetacoplanRTP: Placebo
RTP: Change From Baseline in Muscle Strength at Week 52-0.78 ± 0.06-0.59 ± 0.10
Statistical analysis
  • RTP: Pegcetacoplan vs RTP: Placebo · MMRM · p = 0.0935 · Difference in ls mean: -0.19 · 95% CI -0.42 to 0.03
SecondaryRTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 52

Subjects with an event (that is, either death or permanent tracheostomy or permanent assisted ventilation) in RTP are reported.

Time frame:
Baseline (Day 1) up to Week 52
Reported as:
Count of participants · Participants
RTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 52
ParticipantsRTP: PegcetacoplanRTP: Placebo
RTP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 524227
SecondaryRTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 52

The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related quality of life (QoL) over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was calculated by adding the 5 dimension scores; least squares mean is presented here. Higher scores indicated worse QoL.

Time frame:
Baseline (Day 1) and Week 52
Reported as:
Least squares mean · score on a scale
RTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 52
score on a scaleRTP: PegcetacoplanRTP: Placebo
RTP: Change From Baseline in ALS Assessment Questionnaire (ALSAQ)-40 at Week 5231.3 ± 1.3524.8 ± 1.94
Statistical analysis
  • RTP: Pegcetacoplan vs RTP: Placebo · MMRM · p = 0.0069 · Difference in ls mean: 6.5 · 95% CI 1.8 to 11.1
SecondaryOLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104

The ALSFRS-R included 12 items for assessment of functional status: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking, climbing stairs, dyspnea, orthopnea, and respiratory insufficiency. Each item ranged from 0 (no ability) to 4 (normal ability). Individual item scores were summed to produce a total score between 0 (worst) and 48 (best) with higher scores meaning better outcome. Mean is presented here. Baseline was defined as the last observed value for the efficacy assessment prior to taking the first dose of study drug in OLP.

Time frame:
Baseline (Week 52) and Week 104
Reported as:
Mean · score on a scale
OLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104
score on a scaleOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
OLP: Change From Baseline in the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Score at Week 104-19.0 ± 10.82-28.0
SecondaryOLP: Change From Baseline in Percent Predicted Slow Vital Capacity at Week 104

SVC is a pulmonary function test and predictor of functional loss in ALS. It was planned to be conducted at clinic visits with the clinic spirometer which reflected the maximum amount of air that could be exhaled slowly. %SVC is the actual volume exhaled in the first 1 second, divided by the normal value for that actual value for a person of that age, gender, height and weight. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Week 52) and Week 104

No measurements were reported for this outcome.

SecondaryOLP: Change From Baseline in Muscle Strength at Week 104

Muscle strength was planned to be measured using HHD and assessed the following muscles: first dorsal interosseous, wrist extension, elbow extension, elbow flexion, shoulder flexion, knee extension, knee flexion, and ankle dorsiflexion, on both sides of the body. Baseline was defined as the last available, non-missing observation prior to first study drug administration.

Time frame:
Baseline (Week 52) and Week 104

No measurements were reported for this outcome.

SecondaryOLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104

Subjects with an event of death are reported. Subjects were planned to be assessed for permanent tracheostomy or permanent assisted ventilation in OLP; however, that data was not collected as study was terminated early.

Time frame:
Baseline (Week 52) and Week 104
Reported as:
Count of participants · Participants
OLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104
ParticipantsOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
OLP: Number of Subjects With an Event of Death or Permanent Tracheostomy or Permanent Assisted Ventilation at Week 104106
SecondaryOLP: Change From Baseline in ALS Assessment Questionnaire-40 at Week 104

The ALSAQ-40 was a 40-item validated questionnaire designed to assess health related QoL over the previous 2 weeks in subjects with ALS. It represented 5 dimensions of health status; each scored from 0 (never, or best) to 4 (always, or worst). 5 dimensions evaluated were: physical mobility (10 items: 1-10; possible score of 0-40); activities of daily living/independence (10 items: 11-20; possible score of 0-40); eating and drinking (3 items: 21-23; possible score of 0-12); communication (7 items: 24-30; possible score: 0-28) and emotional functioning (10 items: 31-40; possible score: 0-40). The total score 0 (no impairment) to 160 (severe impairment) was planned to be calculated by adding the 5 dimension scores. Higher scores would have indicated worse QoL.

Time frame:
Baseline (Week 52) and Week 104

No measurements were reported for this outcome.

SecondaryNumber of Subjects With an Event of Death During the Study

Total number of subjects who died in the study are reported.

Time frame:
RTP: Baseline (Day 1) up to Week 52; OLP: Baseline (Week 52) up to Week 104
Reported as:
Count of participants · Participants
Number of Subjects With an Event of Death During the Study
ParticipantsRTP: PegcetacoplanRTP: PlaceboOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
Number of Subjects With an Event of Death During the Study2611106

Adverse events

Collected over TEAEs, TESAEs and deaths were collected from first dose of study drug (RTP: Day 1/OLP: Week 52) up to 56 days post last dose of study drug, approximately 60 weeks each for RTP and OLP.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
RTP: Pegcetacoplan26/169 (15.4%)57/169 (33.7%)124/169 (73.4%)
RTP: Placebo11/80 (13.8%)27/80 (33.8%)55/80 (68.8%)
OLP: Pegcetacoplan/Pegcetacoplan10/97 (10.3%)24/97 (24.7%)31/97 (32%)
OLP: Placebo/Pegcetacoplan6/50 (12%)14/50 (28%)20/50 (40%)
Most frequent serious events
Showing 10 of 74
Most frequent serious events
EventRTP: PegcetacoplanRTP: PlaceboOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
Respiratory FailureRespiratory, thoracic and mediastinal disorders13/1697/804/973/50
Covid-19Infections and infestations7/1692/800/971/50
Pneumonia AspirationRespiratory, thoracic and mediastinal disorders7/1692/804/971/50
Pneumonia BacterialInfections and infestations0/1690/800/972/50
UrosepsisInfections and infestations0/1690/800/972/50
Amyotrophic Lateral SclerosisNervous system disorders6/1693/800/972/50
DysphagiaGastrointestinal disorders3/1693/801/970/50
SepsisInfections and infestations0/1690/803/970/50
DyspnoeaRespiratory, thoracic and mediastinal disorders5/1692/801/970/50
PneumoniaInfections and infestations2/1692/802/970/50
Most frequent other events
Showing 10 of 13
Most frequent other events
EventRTP: PegcetacoplanRTP: PlaceboOLP: Pegcetacoplan/PegcetacoplanOLP: Placebo/Pegcetacoplan
FallInjury, poisoning and procedural complications37/16914/806/971/50
COVID-19Infections and infestations28/16913/806/971/50
ConstipationGastrointestinal disorders12/1697/805/971/50
HypertensionVascular disorders3/1695/801/974/50
PneumoniaInfections and infestations0/1690/804/974/50
DiarrhoeaGastrointestinal disorders10/1695/800/970/50
Urinary Tract InfectionInfections and infestations6/1695/801/973/50
InsomniaPsychiatric disorders8/1695/800/970/50
CoughRespiratory, thoracic and mediastinal disorders7/1695/800/970/50
Pneumonia aspirationRespiratory, thoracic and mediastinal disorders0/1690/802/973/50

Baseline characteristics

The intent-to-treat (ITT) population included all randomized subjects who received at least 1 dose of randomized treatment (pegcetacoplan or placebo).

Age, Continuous
Age, Continuous(years)RTP: PegcetacoplanRTP: PlaceboTotal
Mean57.0 ± 12.4757.7 ± 11.0257.2 ± 12.01
Sex: Female, Male
Sex: Female, Male(Participants)RTP: PegcetacoplanRTP: PlaceboTotal
Female642589
Male10555160
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RTP: PegcetacoplanRTP: PlaceboTotal
Hispanic or Latino271542
Not Hispanic or Latino12462186
Unknown or Not Reported18321
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RTP: PegcetacoplanRTP: PlaceboTotal
Caucasian13067197
Black or African American000
North East Asian14620
South East Asian000
Other13518
Unknown12214
08

Study locations

60 sites
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins
    Baltimore, Maryland 21205, United States
  • The Berman Center
    Minneapolis, Minnesota 55415, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Austin Neuromuscular Center
    Austin, Texas 78756, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Brain and Mind Centre
    Camperdown, New South Wales 2050, Australia
  • Central Coast Neurosciences Research
    Erina, New South Wales 2250, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Gold Coast University Hospital
    Southport, Queensland 4215, Australia
  • Nueor-Immunology Clinical Researh Education and Support Service (N-CRESS), Austin Health
    Heidelberg, Victoria 3084, Australia
  • AZ Sint-Lucas & Volkskliniek
    Gent, B-9000, Belgium
  • Universitaire Ziekenhuizen Leuven (UZ Leuven)
    Leuven, B-3000, Belgium
  • Vseobecna fakultni nemocnice v Praze
    Prague 2, 128 21, Czechia
  • FORBELI s.r.o.
    Prague 6, 160 00, Czechia
  • Hopital Pellegrin
    Bordeaux, 33076, France
  • Hôpital Neurologique Pierre Wertheimer
    Bron, 69677, France
  • CHU Gabriel Montpied
    Clermont-Ferrand, 63000, France
  • Hôpital Roger Salengro
    Lille, 59037, France
  • CHU de Limoges Dupuytren 1
    Limoges, 87042, France
  • CHU de Nice Hôpital Pasteur
    Nice, 6300, France
  • Charité - Universitätsmedizin Berlin
    Berlin, D-13353, Germany
  • Medizinische Hochschule Hannover Klinik für Neurologie
    Hannover, 30625, Germany
  • Universitätsklinikum Jena
    Jena, 07747, Germany
  • Universitätsmedizin Rostock, Klinik und Poliklinik für Neurologie
    Rostock, 18147, Germany
  • University of Ulm
    Ulm, 89081, Germany
  • Beaumont Hospital
    Dublin, DO9 V2NO, Ireland
  • Ospedale Niguarda - Nemo Clinical Center - Fondazione Serena Onlus
    Milano, 20162, Italy
  • Ospedale Civile S. Agostino Estense di Modena, Azienda Ospedaliero Universitaria di Modena
    Modena, 41126, Italy
  • AOUP "P. Giaccone"
    Palermo, 90129, Italy
  • Azienda Ospedaliera Universitaria di Torino - Città della Salute e della Scienza di Torino
    Torino, 10126, Italy
  • National Hospital Organization Higashinagoya National Hospital
    Aichi, 465-8620, Japan
  • National Hospital Organization Omuta National Hospital
    Fukuoka, 837-0911, Japan
  • National Hospital Organization Asahikawa Medical Center
    Hokkaido, 070-8644, Japan
  • National Hospital Organization Hyogo-Chuo National Hospital
    Hyōgo, 669-1592, Japan
  • National Hospital Organization Iou National Hospital
    Ishikawa, 920-0192, Japan
  • National Hospital Organization Matsumoto Medical Center
    Matsumoto, 399-8701, Japan
  • Niigata National Hospital National Hospital Organization
    Niigata, 945-8585, Japan
  • National Hospital Organization Okinawa National Hospital
    Okinawa, 901-2214, Japan
  • National Hospital Organization Higashisaitama National Hospital
    Saitama, 349-0196, Japan
  • Shizuoka Institute of Epilepsy and Neurological Disorders
    Shizuoka, 420-8688, Japan
  • Juntendo University Hospital
    Tokyo, 113-8431, Japan
  • Tokyo Medical University Hospital
    Tokyo, 160-0023, Japan
  • University Medical Center Utrecht
    Utrecht, 3584 CX, Netherlands
  • Uniwersytecki Szpital Kliniczny w Olsztynie Klinika Neurologii
    Olsztyn, 10-082, Poland
  • Centrum Medyczne NeuroProtect
    Warsaw, 01-684, Poland
  • City Clinic Sp. z o.o.
    Warsaw, 02-473, Poland
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Bellvitge University Hospital
    Barcelona, 08907, Spain
  • Hospital Universitari I Politecnic La Fe
    Valencia, 46026, Spain
  • SI Institute of Neurology, Psychiatry and Narcology of NAMSU
    Kharkiv, 61068, Ukraine
  • Centre of Reconstructive and Restorative Medicine (University Clinic) Odessa National Medical University
    Odessa, 65062, Ukraine
  • Zaporizhzhya Regional Clinical Hospital
    Zaporizhzhya, 69600, Ukraine
  • University Hospitals Sussex NHS Foundation Trust
    Brighton, BN2 5BE, United Kingdom
  • Maurice Wohl Clinical Neuroscience Institute, King's College London
    London, SE5 9RX, United Kingdom
  • St George's University Hospitals NHS Foundation Trust
    London, SW17 0WT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2020 to primary completion in Mar 2023, 30 months.

Results were first posted in Apr 2025, 2 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2020
First posted
Oct 8, 2020
StartActual
Sep 30, 2020
Primary completionActual
Mar 31, 2023
CompletionActual
Jul 13, 2023
Results first posted
Apr 24, 2025
Last update
Apr 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04579666
Responsible party
Sponsor
First posted
Oct 8, 2020
Start date
Sep 30, 2020
Primary completion
Mar 31, 2023
Completion
Jul 13, 2023
Results posted
Apr 24, 2025
Last update
Apr 24, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion